CAP23 Abstract Program

Abstracts will be evaluated on the following criteria:

• Significance of the hypothesis
• Valid conclusion(s)
• Argument clarity
• Presentation quality

Important Note: The number of case studies that will be accepted for the CAP23 abstract program will be significantly decreased as compared to past years. Submitting case studies that do not provide new or unique information is strongly discouraged. Case studies that merely report additional cases of a known entity will be rejected.

Case studies must include novel findings, such as the following:

• A new disease or condition (i.e. not previously reported).
• A distinctive or unusual presentation of a known disease, with one or more well-documented new findings of special clinical relevance (i.e., potentially applicable to diagnosis, therapy, prognosis, etc.) or that serves to provide new insight into the possible pathogenesis of a disease (hypothesis-generating). The new information might be derived from distinctive morphology and/or ancillary testing.
• A known disease with a demonstrated new finding using state-of-the-art techniques (immunohistochemical, molecular, 3-dimensional reconstruction, cytogenetics, etc.) relevant to a clearly stated hypothesis.
• A known disease presenting with a previously undescribed clinically or etiologically relevant association (i.e., a myelodysplastic syndrome associated with a plasma cell dyscrasia, etc.) to heighten awareness of a possible link between entities. Such a link might have been described before in one or more individual case reports, and the addition of a case might help solidify a real association.